Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2015 8
2016 9
2017 3
2018 9
2019 12
2020 12
2021 8
Text availability
Article attribute
Article type
Publication date

Search Results

53 results
Results by year
Filters applied: . Clear all
Page 1
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
Tjokrowidjaja A, Lee CK, Friedlander M, Gebski V, Gladieff L, Ledermann J, Penson R, Oza A, Korach J, Huzarski T, Manso L, Pisano C, Asher R, Lord SJ, Kim SI, Lee JY, Colombo N, Park-Simon TW, Fujiwara K, Sonke G, Vergote I, Kim JW, Pujade-Lauraine E. Tjokrowidjaja A, et al. Among authors: kim si. Eur J Cancer. 2020 Nov;139:59-67. doi: 10.1016/j.ejca.2020.08.021. Epub 2020 Sep 23. Eur J Cancer. 2020. PMID: 32977221 Clinical Trial.
Tumor evolution and chemoresistance in ovarian cancer.
Kim S, Han Y, Kim SI, Kim HS, Kim SJ, Song YS. Kim S, et al. Among authors: kim si. NPJ Precis Oncol. 2018 Sep 17;2:20. doi: 10.1038/s41698-018-0063-0. eCollection 2018. NPJ Precis Oncol. 2018. PMID: 30246154 Free PMC article. Review.
53 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page